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Background: Supporting health care sector decisions using time-dependent endpoints (TDEs) such as time to
progression (TTP), progression-free survival (PFS), and event-free survival (EFS) remains controversial. This study
estimated the quantitative relationship between median TDE and median overall survival (OS) in multiple myeloma
(MM) patients.
Methods: Studies (excluding allogeneic transplantation) published from 1970 to 2011 were systematically searched
(PubMed). The nonparametric Spearman’s rank correlation coefficient measured the association between median
TDE and OS. The quantitative relationship between TDEs and OS was estimated with a two-step approach to a
simultaneous Tobit model.
Results: We identified 153 studies: 230 treatment arms, 22,696 patients and mean study duration of 3.8 years.
Mean of median TDEs was 22.5 months and median OS was 39.1 months. Correlation coefficients of median TTP,
PFS, and EFS with median OS were 0.51 (P = 0.003), 0.75 (P < 0.0001), and 0.84 (P < 0.0001), respectively. We estimate
a 2.5 month (95% confidence interval, 1.7–3.2) increase in median OS for each additional month reported for
median TDEs. There was no evidence that this relationship differed by type of surrogate.
Conclusion: TDEs predict OS in MM patients; this relationship may be valuable in clinical trial design, drug comparisons,
and economic evaluation.
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Multiple myeloma (MM) is the second most common
hematologic malignancy, after non-Hodgkin lymphoma
[1,2]. In the US, it was estimated that over 20,500 new
cases of MM and more than 10,600 deaths occurred in
2011 [3]. Despite improved survival over the past de-
cades, MM remains an incurable disease, with research
focused on finding more effective treatments [4]. Al-
though improving overall survival (OS) has been the
gold standard outcome for new anticancer treatments,
large costly trials with long follow-up periods are required
to document an impact on OS [5,6]. Furthermore, OS can
be influenced by trial design characteristics, such as cross-
over and sequential treatments [7,8]. Therefore, surrogate
endpoints that can be measured sooner and more* Correspondence: jorge.felix@exigoconsultores.com
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reproduction in any medium, provided the orfrequently during the course of a clinical trial, are being
used to provide an earlier indication of efficacy [9].
A surrogate endpoint is a measurement that can be
substituted for the final endpoint (e.g., improvement in
OS) to successfully measure the effect of an intervention
[10]. Common surrogate endpoints for OS used in clin-
ical oncology trials include: response rate; time to dis-
ease progression (TTP); progression-free survival (PFS);
and event-free survival (EFS) [6]. For study conclusions
to be valid, differences or changes observed in the surro-
gate endpoints must accurately reflect changes in the
final endpoint [11]. There is ongoing debate about the
utilization of these time-dependent endpoints (TDEs) as
intermediate endpoints for OS in clinical trials [12,13], as
well as their value to health authorities when assessing drug
approvals and assessing costs of drug therapy [7,14,15].
In 1992, the US Food and Drug Administration (FDA)
instituted the accelerated approval process to allowd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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threatening diseases [16]. Recently, the FDA ruled that
both TTP and PFS are valid and clinically relevant TDEs
that can be used in the accelerated approval process for
MM agents [17]. Although these endpoints are generally
thought to be reliable in MM, their predictive value for
OS is unknown. Our objective was to estimate a quantita-
tive relationship between median TDEs and median OS
from prospective published MM studies in order to ad-
dress the question of what the expected median OS would
be given the observed effect in the median TDE.
Methods
Search strategy and selection criteria
We systematically searched PubMed for articles pub-
lished between January 1970 and February 2011 to iden-
tify experimental or observational prospective studies
that assessed OS in MM using TTP, PFS, or EFS as a
primary endpoint. Key search words included “myeloma”
or “survival” or “progression”; see Additional file 1 for
full search details. Retrospective studies were excluded,
as were studies involving allogeneic transplantation,
which generally target younger patients with a clinical
status that differs greatly from the majority of MM pa-
tients. The TDEs considered were median TTP, PFS, and
EFS. The final outcome measures considered were me-
dian OS, 12-month OS, 24-month OS, 36-month OS, or
any survival data that described the proportion of pa-
tients alive or deceased and the duration of follow-up.
Studies lacking surrogate endpoint outcomes or OS data
were excluded; see Additional file 1 for the selection
process scheme. The following variables were collected:
authors, publication year, journal, study sample character-
istics (period of analysis, median age, percentage of males,
type and number of previous therapies), and study results
(therapies used, median TDEs, median OS, 12-month OS,
24-month OS, and 36-month OS).
Statistical methods
Using the median TDE as an independent observation
to estimate median OS, with each study arm representing
a single observation, presents a statistical challenge. Out-
come measures such as TTP, PFS, and EFS differs on their
exact definition, especially with the inclusion or exclusion
of death as event [17]. Concerning the estimation of the
statistical model, this points to the presence of endo-
geneity of the main regressor of interest (TDE) and het-
erogeneity of observations. In the context of linear
regression, an estimation based on an instrumental vari-
ables approach may be considered, when the endogeneity
of regressors is suspected [18].
In addition, the data analyzed are sourced from a lit-
erature review of studies with different study designs,
patient populations, and treatments. It is possible thatthe variance of the unexplained share (the residuals) dif-
fers among observations and that heteroskedasticity
(non-constant variance) is present. In the presence of
heteroskedasticity, the instrumental variables estimator
yields consistent, but inefficient, estimates of the coeffi-
cients and an inconsistent estimate of the covariance
matrix [19]. One way to minimize inefficiency in the co-
efficient estimates is to weight each observation by the
number of patients enrolled in the corresponding study
arm and to use the Generalized Method of Moments
(GMM) [19]. Inconsistency of the standard error esti-
mates may be corrected by using heteroskedasticity ro-
bust estimators of the variance–covariance matrix, such
as the Huber/White sandwich estimator [20,21].
The set of available exogenous variables (candidates
to instruments) comprise the following: 12-months OS
rate; proportion of females; median age; dummy vari-
ables characterizing patients by previous treatment; type
of TDEs; and publication year.
Not all study arms included in the review reached the
median OS by the last published follow-up; those that
did not are censored observations. If, at the end of a
given study, less than 50% of the patients at risk were
alive, then the exact value of the dependent variable being
modeled (median OS) is known. However, if the duration
of the study is shorter than the number of months needed
to have less than 50% of patients alive, then all that is
known about the dependent variable is that it is higher
than the study duration. This information is potentially
relevant and was included in our analysis.
The estimation of the censored model with one en-
dogenous variable (TDE) was performed by a two-step es-
timation process similar to the method developed by
Smith and Blundell [22], with the following modifications:
(i) The regression of the endogenous variable on the
excluded instruments and exogenous variables (Step
1) was weighted by the number of patients in each
study arm and estimated using the GMM Cragg
estimator [23]. This estimator makes use of
information provided by the excluded instruments
(median age, percentage of males, and classification
of patients by number of previous treatments) to
increase efficiency in the presence of
heteroskedasticity of unknown form.
(ii) Given that the censoring point varies with the study
arm, a censored normal-weighted regression with
the robust option [21] was estimated in Step 2,
instead of a purely Tobit model.
Following the approach described in Smith and Blundell
(1986) [22], variance of the estimators’ formulas was
corrected for one endogenous regressor. With such cor-
rections Smith and Blundell demonstrate that estimates
Table 1 Characteristics of the studies and patients
included in the analysis
Characteristic (n = 22,696)
Males,% 56.5
Age in years, mean of medians ± standard deviationa 61.3 ± 7.2
Multiple myeloma, no. of patients (study arms)
Newly diagnosed 15,345 (128)
Relapsed, refractory, or advanced 5,273 (68)
Mixed or not reportedb 2,078 (34)
Duration of the studies (years),
mean ± standard deviation
3.8 ± 2.0
Mean of median time-dependent endpoint, months (range) 22.5 (3–121)
Time to progression 16.7 (4–39)
Progression-free survival 22.7 (5–121)
Event-free survival 25.7 (3–70)
Median overall survival in months, mean (range) 39.1 (8–126)
aAge statistics represent the mean of medians because the majority of studies
reported the median rather than the mean age of the studied population.
bCorresponds to those studies including: newly diagnosed; relapsed, refractory,
or advanced; or to those not differentiating the type of patients.
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(CIs) are asymptotically valid and hence applicable in the
context of the present analysis.
Evidence in favor of the use of the instrumental vari-
able approach was generated by the Durbin-Wu-Hausman
test for endogeneity of the TDE regressor [24-26]. The
validity of the instruments used was confirmed by both a
high degree of correlation between the instruments
and the endogenous regressor and the orthogonality be-
tween the endogenous regressor and the error term
(Hansen J-statistic) [27]. The Breusch-Pagan test for het-
erogeneity [28] was used to check for the adequacy of the
GMM estimator. The selection of the final functional form
of the model was based on the RESET test [29], a test that
checks the possible omission of relevant variables or, more
specifically, validates the linearity assumption.
Alternative model specification was based on three cri-
teria: validity of the instruments used; explanatory power
of the instruments in the first-stage regression; and AIC
(Akaike Information Criteria) in the second-stage (cen-
sored) regression.
The association between median TDE and median OS
was quantified through Spearman’s rank correlation co-
efficient in a restricted subset of data consisting of trials
only with simultaneously observed values for median
TDE and median OS, and excluding those trials with un-
observed median OS values [30,31]. This complete-case
analysis is known to result in loss of accuracy and preci-
sion when the data are not missing completely at ran-
dom [32], but was assumed in order to avoid data
imputation methods or assumptions about the distribu-
tion of the unobserved median OS values. The analysis
was performed with the Stata Statistical Software (Re-
lease 11. College Station, TX: StataCorp LP).Results
Sample characteristics
Of the 1,061 studies retrieved, we included 153 studies
involving 230 study arms (see Additional file 1). The pri-
mary endpoints reported were: median TTP (n = 46);
median EFS (n = 76); and median PFS (n = 108). Of the
230 study arms, 163 reported median OS (67 unob-
served values). The 12-, 24-, and 36-month OS rates
were reported in 100%, 73%, and 70% of the study arms,
respectively. Overall, the sample included 22,696 MM
patients, 56.5% of whom were male (Table 1). Each arm
included an average ± standard deviation of 99 ± 80 pa-
tients (range 8–345). The mean of reported median
age was 61.3 ± 7.2 years (range 44–79), and the majority
of arms (67.6%) represented only newly diagnosed or
treatment-naïve patients. Mean of median TDEs was
22.5 ± 15.2 months (range 3–21), and the mean of me-
dian OS was 39.1 ± 18.4 months (range 8–126).Correlation between TDEs and OS
The Spearman’s rank correlation coefficient of the ag-
gregated median TDE data on median OS was 0.78
(P < 0.0001). Figure 1 shows the correlation between me-
dian values of the TDEs and median values of observed
OS. The nonparametric Spearman’s rank correlation coef-
ficient value (ρ) was highly significant for all TDEs, with a
moderate correlation between median OS and median
TTP (ρ = 0.51), and a strong correlation for median PFS
(ρ = 0.75) and median EFS (ρ = 0.84).
Modeling the effect of TDE on OS
Table 2 reports the regression of identified variables in
median OS. Regression coefficients (β) correspond to
the estimated effect of each variable controlled for the
effect of all other variables included in the model. The
95% CIs including zero identify a non-significant effect.
We found an increase of 2.45 months (95% CI, 1.71–
3.20) in the reported median OS for each additional
month in the observed median TDE (Table 2). This esti-
mate was obtained adjusting for differences in the study
demographics, patient type, surrogate endpoint type,
publication year, and MM treatments including thalido-
mide (Thal), bortezomib (Bort), or lenalidomide (Len).
All other covariables used in this multivariate censored-
normal regression model have non-significant coeffi-
cients, suggesting a weak explanatory power on median
OS in the presence of the highly significant TDE regres-
sor (P < 0.0001). These results also suggest a borderline
significant positive association (P = 0.06) between trials
including patients with relapsed, refractory, or advanced
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Figure 1 Correlation between median values of the time-dependent endpoints (TDEs) and observed median overall survival (OS). Each
circle represents a study arm, and the surface area of the circle is proportional to the size of the arm. The nonparametric Spearman’s rank correlation
coefficient (ρ) and its level of significance are also reported. Abbreviations: EFS, event-free survival; PFS, progression-free survival; TTP, time to progression.
Table 2 Effect of median time-dependent endpoints
(TDEs) on median overall survival (OS) estimated from a
multivariate censored normal regression, by type of TDE
Covariables β SE P 95% CI
Median TDE, months 2.45 0.38 < 0.0001 1.71 ; 3.20
Females,% 0.05 0.24 0.83 − 0.42 ; 0.52
Median age, years 0.59 0.38 0.12 − 0.16 ; 1.34
Year of publication 0.24 0.32 0.46 − 0.39 ; 0.87
Relapsed, refractory,
or advanced MM
14.24 7.60 0.06 − 0.66 ; 29.14
Mixed or not reported
type MM
6.95 5.02 0.17 − 2.89 ; 16.78
TDE (time to progression) 5.95 4.16 0.15 − 2.21 ; 14.11
TDE (event-free survival) − 3.51 4.03 0.38 − 11.42 ; 4.40
Treatment including Thal,
Bort, or Len
− 5.98 6.08 0.33 − 17.89 ; 5.94
Note: Includes 163 uncensored observations and 67 right-censored
observations. The constant of the model was suppressed due
to non-significance.
Abbreviations: β Regression coefficient, Bort Bortezomib, CI Confidence interval
Len Lenalidomide, MM, Multiple myeloma, SE, Standard error,
Thal Thalidomide.
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factors not included in the regression model may comple-
ment the TDE explanatory power in relapsed, refractory,
or advanced MM OS. The type of surrogate endpoint and
treatment did not impact the explanatory power to me-
dian OS, which suggests surrogacy of TTP, PFS, and EFS
to OS.
We also tested our modeling technique against a set of
alternative specifications and data samples (censored vs
uncensored) to assess the robustness of the quantitative
relationship between median TDEs and median OS. The
departure model identified in Table 3 as base model
includes covariables to control for differences in age,
gender, and year of publication across studies. Two sets
of data were used: sample without censored observa-
tions including only those studies reaching median OS
(n = 163); and a larger dataset with 67 additional obser-
vations including studies not reaching median OS at
the last published follow-up (sample with censored
observations, n = 230). In this table, all β were highly
significant (P < 0.0001). The inclusion of TTP and EFS
as covariables relative to PFS revealed no statistical
Table 3 Effect of median time-dependent endpoints (TDEs) on median overall survival estimate based on alternative
modeling specifications
Specification With censored observations (n = 230) Without censored observations (n = 163)
β SE 95% CI β SE 95% CI
Base model (BM)a 1.82 0.134 1.56 ; 2.08 2.09 0.206 1.69 ; 2.50
BM without two
perturbing observations
1.84 0.137 1.58 ; 2.11 2.16 0.218 1.73 ; 2.58
BM with adjustment for type
of patient and type of TDEb
2.36 0.344 1.69 ; 3.04 2.64 0.568 1.52 ; 3.75
BM with adjustment for type of patientc,
type of TDE and treatment including Bort,
or Len, or Thal
2.45 0.381 1.71 ; 3.20 2.62 0.558 1.52 ; 3.71
aThe BM is adjusted for age, gender, and year of publication.
bType of TDE refers to time to progression, progression-free survival, and event-free survival.
cType of MM patient refers to the following groups: newly diagnosed; relapsed, refractory, or advanced; and mixed or not discriminated in the publication.
Abbreviations: β Regression coefficient, Bort Bortezomib, CI Confidence interval, Len Lenalidomide, MM Multiple myeloma, SE Standard error Thal Thalidomide.
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of the estimate coefficient of the linear regression rela-
tive to the base model. These results suggest that in tri-
als using PFS, the quantitative relationship between PFS
and OS is not statistically different to the comparison
between TTP or EFS, and OS. However, caution is
recommended in interpreting this result because the nu-
meric differences may point to relevant differences in
bigger samples. Augmenting the model with information
on MM treatment with Thal, Bort, or Len (sample with
censored observations) increased the TDE coefficient
from 2.36 to 2.45. Despite these therapies not being sta-
tistically significant relative to other treatments, they
were retained in the model to control for unobserved
differences in trials using newer treatment options com-
pared with older treatments. This does not imply that
Thal, Bort, and Len have no effect on OS, but instead
suggests that these compounds do not add more ex-
planatory power on median OS other than their effect
through median TDE.
Overall, the consistency of the estimated values for the
effect of median TDE on median OS is evident. The
maximum variation in the effect of median TDE on me-
dian OS is 34% (β = 2.45; 95% CI, 1.71–3.20) relative to
the base model (β = 1.82; 95% CI, 1.56–2.08).
Results based on the sample with uncensored observa-
tions provide higher effect values, most likely related to
the study design. In our sample, phase II and phase III
randomized controlled trials (RCTs) represent 38.8% and
46.3%, respectively, of the study arms with censored ob-
servations, and 23.9% and 55.2%, respectively, of the study
arms without censored observations. The results from the
regression models including and excluding the two out-
liers are quite similar, indicating the small effect of these
two observations in the analysis.
Additional details of the statistical tests performed to
assess the validity of the modeling procedures can be
found in the Additional file 1.Prediction of median OS from the observation of median TDE
The detailed predicted median OS and associated 95% CIs
based on the observed median TDE for each study arm
included in our analysis are presented in the Additional
file 1. In general, lower predicted median OS values in
the study arms using TTP were found. TTP is the only
TDE that does not include death. There was a higher pro-
portion of study arms using TTP as the primary endpoint
in the relapsed, refractory, or advanced MM population
(46%) compared with 26% and 25% of the study arms
evaluating PFS and EFS, respectively. In addition, 35.5%,
63.7%, and 58.0% of the observed median OS are
contained in the 95% CI prediction for the TTP, PFS, and
EFS, respectively. In approximately one-third of the TTP
arms, median OS is under-observed relative to the 95%
CI. In the PFS subset, 26.3% of arms reported median OS
below the predicted 95% CI and 10% above it. In the EFS
subset, 36% of arms report median OS below the pre-
dicted 95% CI and 6% above it.
A selection of RCTs retrieved from three recent re-
views [33-35] investigating treatment options for newly
diagnosed MM in patients not eligible for transplan-
tation [36-49], the relapsed/refractory MM setting [50-52]
and post-transplantation maintenance therapy [53-59],
respectively, were used to illustrate the practicality of our
method in predicting median OS from observed data on
median TDE. Figures 2, 3, 4 plot the predicted median OS
and associated 95% CIs in comparison with the observed/
reported median OS, including those that did not report
the median OS due to a short follow-up period. It should
be noted that the RCTs presented in these figures are
very heterogeneous in their design, patient populations,
and treatment options, with some including maintenance
therapy. This is not an exhaustive sample of all RCTs, but
simply represents a selection of published trials that report
median PFS or TTP or EFS.
Since 2007, results from 8 phase III trials investigating
Thal combinations in patients with newly diagnosed
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Figure 2 Predicted median overall survival (OS) versus the observed OS in randomized controlled trials (RCTs) including thalidomide-,
bortezomib-, or lenalidomide-based regimens for upfront treatment of multiple myeloma in patients not eligible for transplantation.
Horizontal lines represent estimated 95% confidence interval (CI) for the median OS based on the modeled median time-dependent endpoints
from each study arm. Solid circles represent observed median OS contained in the corresponding 95% CI estimate, and lozenges represent
observed median OS not contained in the corresponding 95% CI estimate. Where data are from different studies, a direct comparison is not
possible as different studies use different patient populations, different study designs, and were conducted at different time points. Vertical
dashed line stands for the mean of median OS of the MP arms. a19.5% of trial patients received thalidomide maintenance therapy. b88% of
patients received thalidomide maintenance therapy. c18.8% of trial patients received thalidomide maintenance therapy. d33–55% of trial patients
received bortezomib maintenance therapy. e35% of trial patients received maintenance therapy with bortezomib plus prednisone and 33.5% with
bortezomib plus thalidomide. f66.7% of patients received maintenance therapy with bortezomib plus thalidomide. g100% of patients planned to
receive maintenance therapy with lenalidomide. Abbreviations: CTDa, attenuated (low-intensity) cyclophosphamide, thalidomide, dexamethasone;
MP, melphalan, prednisone; MPR, melphalan, prednisone, lenalidomide; MPR-R, melphalan, prednisone, lenalidomide followed by maintenance
with lenalidomide; MPT, melphalan, prednisone, thalidomide; Rd, lenalidomide, low-dose dexamethasone; RD, lenalidomide, dexamethasone;
TD, thalidomide, dexamethasone; VD, bortezomib, dexamethasone; VMP, bortezomib, melphalan, prednisone; VMPT-VT, bortezomib, melphalan,
prednisone, thalidomide followed by maintenance with bortezomib, thalidomide; VTP, bortezomib, thalidomide, prednisone.




Richardson et al. [51] (arm Bort, n = 333)
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Figure 3 Predicted median overall survival (OS) versus the observed OS in phase III randomized controlled trials (RCTs) including
bortezomib- or lenalidomide-based regimens for the treatment of relapsed/refractory multiple myeloma. Horizontal lines represent
estimated 95% confidence intervals (CIs) for the median OS based on the modeled median time-dependent endpoints from each study arm.
Solid circle represents observed median OS contained in the corresponding 95% CI estimate, and lozenges represent the observed median OS
not contained in the corresponding 95% CI estimate. Where data are from different studies, a direct comparison is not possible as different
studies use different patient populations, different study designs, and were conducted at different time points. Vertical dashed line stands for the
mean of median OS of the Dex arms. Abbreviations: Bort, bortezomib; Dex, dexamethasone; Len, lenalidomide; PLD, pegylated liposomal doxorubicin.
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With the exception of the studies by Ludwig et al. [36]
and Morgan et al. [37], all other studies compare Thal
added to melphalan plus prednisone (MPT) with mel-
phalan plus prednisone (MP). The majority of median
OS values reported (13/16) are within our 95% CI esti-
mate for OS, confirming the value of TDE in predicting
OS (Figure 2). Another practical implication from our
method is that once median TTP/PFS/EFS is observed,
we can derive an estimate for the median OS even if
it has not been reported. The OS estimates can be used
to inform decision makers on newer and promising MM
treatment regimens, along with other relevant clinical
parameters such as acceptable tolerability, favorable
safety profile, and sustainable quality-of-life outcomes.
In Figure 3, we present the estimated median OS vs
the observed OS in phase III RCTs using Bort- or Len-
based regimens for the treatment of relapsed/refractory
MM. The only treatment arm reporting median OS
within the 95% CI from our model is the Len plus dexa-
methasone (Dex) arm from the study by Dimopoulos
et al. [50]. At first glance, these results suggest that
our model is less suitable for predicting median OS in
relapsed/refractory MM. However, it should be noted
that the effect from subsequent salvage therapies is
expected to be more pronounced, with a shorter median
TDE, i.e. the faster progression occurs.
A recent review by Reece [35] identified several phase
III RCTs of post-transplantation maintenance therapy
with Thal, Len, and the proteasome inhibitor Bort. These
studies differ substantially in the type of induction regi-
men, transplantation strategy (single vs tandem) andmaintenance scheme (drug combinations, doses, and
duration). However, this heterogeneity provided us with
the opportunity to further evaluate our model. Figure 4
incorporates updated survival outcomes from these trials
and presents estimations for the median OS. Trials iden-
tified in Reece [35] that did not report median inter-
mediate TDE were not considered in this figure. The
study by Lokhorst et al. [56] was the only one from this
set to contribute with data to our regression model. At
present, we can estimate an average absolute increase of
27 months, 17 months, and 47 months in median OS
for post-transplantation maintenance therapy with Thal,
Bort, and Len, respectively.
Discussion
There is a sound body of evidence suggesting that TDEs
such as PFS, TTP, and EFS are appropriate surrogate
endpoints for OS in several types of cancer [31,60-71].
However, some conflicting evidence [61,72,73] and some
methodological [11], regulatory [74], and conceptual/
practical [75] arguments fuel the ongoing discussion about
surrogate endpoints in the cancer literature [76-78] and
challenge the establishment of TDEs in oncology clinical
development [79].
Our study is the first to highlight the value of TDEs in
predicting OS in MM and to confirm the recommenda-
tions of the American Society of Hematology/US FDA
Workshop on Clinical Endpoints in both newly diag-
nosed or relapsed/refractory MM [17]. We focused our
research on estimating the absolute effect of TDEs on
OS rather than using a relative measure. We are aware
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Figure 4 Predicted median overall survival (OS) versus the observed OS in randomized controlled trials (RCTs) including thalidomide-,
bortezomib-, or lenalidomide-based regimens for post-transplantation maintenance therapy in multiple myeloma. Horizontal lines
represent estimated 95% CIs for the median OS based on the modeled median time-dependent endpoints from each study arm. Solid circles
represent observed median OS contained in the corresponding 95% CI estimate, and blue lozenge represents observed median OS not
contained in the corresponding 95% CI estimate. Vertical dashed line stands for the mean of median OS of the no maintenance arms.
Abbreviations: Bort, bortezomib; Dex, dexamethasone; Len, lenalidomide; Thal, thalidomide.
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establishing that the surrogate endpoint predicts the
final endpoint accurately; 2) demonstrating that the
effect of treatment on both the surrogate endpoint and
the final endpoint is closely correlated [11]. Our method-
ology, while inherently considering the two last criteria,
follows a less formal [80] approach by using regressionmodeling methods to show that the effect on median OS
is captured by the TDE (validation criterion 1) and that
adding treatment to the linear predictor does not improve
the prediction (validation criterion 2) (i.e. does not im-
prove the fit), hence suggesting that the causal link be-
tween treatment and endpoint has been captured by the
TDE predictor.
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in different settings, we confronted our estimates with
data from studies in relapsed/refractory MM led by
Dimopoulos et al. [50] and Richardson et al. [51]
(Figure 3). The study by Dimopoulos et al. comparing
Len plus Dex with Dex alone reported a hazard ratio
(HR) for progression of 0.31 (median 13.4 vs 4.6 months)
[81], and for death of 0.71 (median 38.0 vs 31.6 months)
[50]. In the study by Richardson et al., which compared
Bort to Dex, the reported HR for progression was 0.55
(median 6.2 vs 3.5 months) [82] and for death was 0.77
(median 29.8 vs 23.7 months) [51].
Estimates of median OS using our model suggest an
HR for death of 0.34 for Len plus Dex vs Dex alone
(median OS 33 vs 11 months), and 0.55 for Bort vs Dex
(median OS 15 vs 9 months), assuming event times are
exponentially distributed [83]. In this case, the treatment
effect on TTP would explain more than 90% of the treat-
ment effect on OS for both Len plus Dex and for Bort.
It has been argued that OS is not a realistic endpoint in
this setting [84], especially considering the ever increasing
availability of new, effective drugs that can be used as
salvage therapies [8,85] which may mask the real survival
differences between treatment arms. Statistical methods to
correct for bias resulting from non-informative censoring
(crossover and subsequent treatment options) in survival
analysis are increasingly popular [86,87]. In a recent paper
by Ishak et al. [88], information from trials conducted by
the Medical Research Council (United Kingdom) was
used to calibrate survival regression analyses in order to
reproduce survival estimates corrected for patient cross-
over in clinical trials. These authors present a median OS
of 11.6 months (95% CI, 9.5–14.2) for patients with > 1
prior therapy randomized to Dex [50], which is similar to
our estimate of 11.3 months. Furthermore, in a survival
analysis adjusted for crossover in the APEX trial, Pacou
et al. report an OS HR of 0.59 for Bort relative to Dex
[89], which is also very similar to the value derived from
our model (HR 0.55), suggesting that our model performs
accurately in trials with substantial crossover. Nonethe-
less, caution is recommended for extrapolation outside
the context of our sample because more mature data on
more recent clinical trials and future research in this topic
is clearly needed.
We provide a more straightforward way of calculating
the expected effect of treatment on median OS (prior to
the observation of mature OS data), by estimating an ab-
solute rather than a relative measure for the quantitative
relationship between the median TDE and median OS.
This regression model recognizes the influence of sub-
sequent therapies because it estimates a mean effect of
median TDE on median OS using OS data published in
the literature, which is uncorrected for the effect of non-
randomized subsequent treatment options. We estimatedan average increment of 2.45 months in median OS for
each additional month of median TDE. As previously
highlighted, these estimates are valuable to assess the
expected impact of treatments on median OS, for example
in trials of newly diagnosed MM where median OS may
not be reached for several years.
Information on survival is essential for clinical trial de-
sign [90], accelerated approvals for new drugs [91], in-
direct drug comparisons, and economic considerations
(e.g. formulary inclusion and other reimbursement deci-
sions), particularly in the absence of head-to-head com-
parative clinical trials. Such information may help clinicians
select the most suitable treatment options for MM patients.
Other studies examining the relationship between
TDEs and OS have been reported in metastatic colorec-
tal cancer (mCRC) [31,62] and in metastatic breast can-
cer [72]. In mCRC, there was a strong association
between PFS and OS [31,62], with similar correlation co-
efficients as obtained in our analysis of MM patients
[62]. In metastatic breast cancer, no particular endpoint
was determined to be an adequate surrogate for OS [72].
The different conclusions from studies in breast cancer,
mCRC, and MM emphasize the fact that appropriate
TDEs cannot be generalized in oncology, and their valid-
ity depends on tumor type.
The following caveats should be considered when
interpreting our results. Although it seems reasonable to
question the endogeneity of TDEs as an explanatory
variable for OS, this issue has not been addressed in the
MM literature. The methodology presented here at-
tempts to solve the endogeneity problem, but its applic-
ability depends on the availability of valid instruments.
In this analysis, TDEs include three distinct surrogate
endpoints; TTP, PFS, and EFS. The estimated relation-
ship between the TDE and OS represents the relation-
ship between an “average” TDE and OS. Although no
statistical differences have been found in modeled OS by
the type of TDE, the value of the information is limited.
Further studies are necessary, particularly to clarify the
data from studies using TTP, both because of the com-
peting risk estimation problems [92] and the arguments
against the use of TTP [7]. Testing could be performed
by either modeling each of the subsamples or by includ-
ing an interaction term between the TDE and type of
surrogate endpoint marker in the regression. In the
current analysis, no testing could be performed due to the
sample size and need for additional (valid) instruments.
Our analysis includes therapies available over a period
of 40 years that demonstrated a wide range of efficacy
levels. We attempted to control these differences by using
publication year as a covariate. In addition, our censored
analysis omitted treatment arms with proportionally lon-
ger median OS and therefore may not reflect adequately
the impact of newer, more effective therapies. Finally, the
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included patients who were allowed to crossover between
treatment arms. Study designs that include automatic
treatment crossover can obscure differences in OS, due to
the benefit achieved from subsequent treatments [8].
Conclusion
In conclusion, our analysis confirms the potential value of
TDEs (TTP, PFS, and EFS) in predicting OS in patients
with MM. Additional research is welcomed to refine this
model or to identify alternative complementary statistical
models. Until such models are available and validated, the
quantitative relationship presented here may be of value
in the design of clinical trials, indirect drug comparisons,
and economic assessment of new MM drugs.
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